Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 439

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

American Diabetes Association Standards of Medical Care in Diabetes 2017

Open access
Marathe, Payal H., Gao, Helen X., Close, Kelly L.·2017·Journal of Diabetes

Abstract

The American Diabetes Association’s (ADA) 2017 Standards of Care1 were published in Diabetes Care on 15 December 2016. Notable changes in the new guidelines include the recommendation of sodium-glucose cotransporter 2 (SGLT-2) inhibitor empagliflozin and glucagon-like peptide 1 (GLP-1) agonist liraglutide for type 2 diabetes (T2D) patients at high risk for cardiovascular morbidity and mortality. Data from the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial2 and the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial3 are now included in the section on cardiovascular disease and risk management. In addition, fixed-ratio combinations of a basal insulin and a GLP-1 agonist are included in the algorithm for combination therapy, just weeks after the first of these products, Novo Nordisk’s (Copenhagen, Denmark) Xultophy (insulin degludec/liraglutide) and Sanofi’s (Paris, France) Soliqua (insulin glargine/lixisenatide), were approved by the US Food and Drug Administration (FDA) for prescription in the US. Based on recommendations from the International Hypoglycemia Study Group,4 the ADA’s 2017 Standards of Care features a new classification for hypoglycemia: clinically significant hypoglycemia is now defined at blood glucose levels <54 mg/dL, whereas blood glucose levels <70 mg/dL should be used as an “alert value” to help individuals avoid more severe hypoglycemia. The ADA’s new guidelines also include a greater emphasis on cost of diabetes drugs, T2D prevention (with a push for more frequent prediabetes screenings), and psychosocial support in diabetes care, especially for adolescents and pediatric patients. The 14th Annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease took place in Los Angeles (CA, USA) from 1 to 3 December 2016, drawing almost 500 attendees. A presentation on the promise of fibroblast growth factor (FGF)-1 in reversing insulin resistance discussed how FGF-1 administration to genetically obese mice can normalize blood glucose levels, improve insulin sensitivity, and lower liver fat levels through action at the adipocyte FGF-1 receptor. Although FGF-1 has a short half-life when administered systematically, studies of optimized FGF-1 analogs have demonstrated the possibility of longer-term glucose-lowering effects. These analogs offer the added benefit of no thiazolidinedione (TZD)-like side effects, and could present a management of T2D. This meeting featured a discussion of the TZD class of agents as well, and a presentation of major findings from the Insulin Resistance Intervention after Stroke (IRIS) trial.5 Treatment with the insulin-sensitizing TZD pioglitazone over the course of 5 years reduced the relative risk of stroke and myocardial infarction by 24% (P = 0.007), reduced the incidence of new-onset diabetes by 52% (P < 0.001), and reduced the relative risk of acute coronary syndrome by 25% compared with placebo. All participants in the IRIS trial were patients with a recent history of stroke or transient ischemic attack who were found to have insulin resistance, but who did not have diabetes (n = 3876). Thiazolidinediones have been associated with undesirable side effects, namely weight gain and edema, although this side effect profile is thought to be more benign with lower doses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1753-0407.12524

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 439

Metadata

Authors
Marathe, P. H., Gao, H. X., & Close, K. L.
Venue
Journal of Diabetes
Publisher
Wiley
Published
2017-03-13
Volume
9
Issue
4
Pages
320-324
ISSN
  • 1753-0393 (ISSN-L)
  • 1753-0407
OpenAlex
W2570161819
Cited by
439
References
8
FWCI
47.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: American Diabetes Association Standards of Medical Care in Diabetes 2017. https://app.cochat.ai/papers/10.1111/1753-0407.12524
The paper
Marathe, P. H., Gao, H. X., & Close, K. L. (2017). American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12524

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.